Tag: gross proceeds

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of cutting-edge radio frequency (“RF”) power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, announces that the Company closed the first tranche of the non-brokered private placement of units (the “Units”) that it previously announced on June 30, 2025 (the “Private Placement”) and distributed a total of 7,913,342 Units, at a price of $0.10 per Unit, for total gross proceeds of $791,334.20. It is anticipated that one or more subsequent tranches of the Private Placement will be closed in due course.

TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- European Residential Real Estate Investment Trust (“ERES” or the “REIT”) (TSX:ERE.UN) announced today an update on the expected timing of its previously disclosed disposition, and its anticipated special distribution, as disclosed in its press release dated April 2, 2025. ERES also announced approximately €52.8 million in additional strategic dispositions, and an intention to cease its regular monthly distributions. All amounts disclosed herein exclude transaction costs and other adjustments.

TAICHUNG CITY, Taiwan, July 31, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced the closing of its previously announced initial public offering of an aggregate 1,250,000 ordinary shares of the Company (the “Offering”) at a price of $4.00 per share (the “Offering Price”).

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions.

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000, and to settle $67,400 owing pursuant to an arm’s length note payable by the issuance of 3,209,523 units, at a price of $0.021 per unit, being the same issue price and security being offering pursuant to the private placement.

INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, reported today its operating results for the second quarter ended June 30, 2025. For the quarters ended June 30, 2025 and 2024, net income attributable to common shareholders was $110.3 million, or $0.50 per diluted share, compared to a net loss of $48.6 million, or $0.22 per diluted share, respectively. For the six months ended June 30, 2025 and 2024, net income attributable to common shareholders was $134.0 million, or $0.61 per diluted share, compared to a net loss of $34.5 million, or $0.16 per diluted share, respectively.